Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMB-365 and TMB-380 combination in HIV-1 suppressed patients
NCT05275998Phase 2Completed
- Sponsor
- TaiMed Biologics
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 2, open-label trial of TMB-365 and VRC07-523LS in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by TaiMed Biologics. Primary endpoints: Safety of TMB-365 and TMB-380 Given Intravenously at 28 weeks, Pharmacokinetics of a Single Dose TMB-365 Given Intravenously at 8 weeks and 4 more. Started Jul 2022; status: completed.
02
Drugs
TMB-365VRC07-523LS
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05275998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275998.